Results show that rifampin enhances the expression of key inflammatory factors while reducing anti-inflammatory mediators in DCs. Moreover, rifampin treatment enhances the immune-stimulatory capabilities of OSCC lysate-loaded-DCs, potentially improving their effectiveness in cancer immunotherapy.

P2, N=60, Active, not recruiting, University of Cape Town | Recruiting --> Active, not recruiting

P3, N=1050, Recruiting, Huashan Hospital | Phase classification: P=N/A --> P3 | N=3000 --> 1050 | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

P3, N=120, Recruiting, Huashan Hospital | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2027 --> Feb 2027

SB218078 emerges as a promising dual-action therapeutic candidate for breast cancer, simultaneously blocking angiogenesis and EMT through the Chk1-ZEB1 axis. Its specificity for ZEB1, distinct from other EMT regulators, offers a novel strategy to overcome the limitations of traditional VEGFR2 inhibitors, warranting further preclinical development.

P1/2, N=30, Recruiting, NexThera Co., Ltd. | Not yet recruiting --> Recruiting

P1/2, N=24, Active, not recruiting, iOnctura | Recruiting --> Active, not recruiting | Trial completion date: Feb 2025 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

P2/3, N=182, Active, not recruiting, Johns Hopkins Bloomberg School of Public Health | Trial completion date: Mar 2025 --> Dec 2025

P1, N=28, Recruiting, Ocugen | Not yet recruiting --> Recruiting | Trial completion date: Sep 2023 --> Oct 2025 | Trial primary completion date: Sep 2023 --> Sep 2025

P=N/A, N=1600, Not yet recruiting, Washington University School of Medicine

P=N/A, N=211, Recruiting, Leiden University Medical Center | Trial completion date: Apr 2024 --> May 2028 | Trial primary completion date: Apr 2024 --> May 2028

P3, N=690, Not yet recruiting, University of California, San Francisco | Trial completion date: Nov 2029 --> Jun 2031 | Initiation date: Jan 2025 --> Oct 2026 | Trial primary completion date: Jun 2029 --> Dec 2030

P1, N=60, Recruiting, Karen Reckamp, MD, MS | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2025 --> Jan 2027

P=N/A, N=30, Active, not recruiting, University of Liverpool | Trial completion date: Dec 2024 --> Dec 2026

These findings demonstrate that rifampicin inhibits melanogenesis through multiple signaling pathways, including PKA, MAPKs, and GSK-3β/β-catenin. This study highlights the potential of rifampicin to be repurposed as a topical agent for managing hyperpigmentation disorders, offering valuable insights into novel therapeutic strategies for pigmentation-related conditions.

RRS1 inhibits angiogenesis and cisplatin resistance of lung cancer cells by activating ferroptosis mediated by p53 pathway.

P3, N=100, Suspended, Rush University Medical Center | Trial completion date: Dec 2025 --> Dec 2027 | Recruiting --> Suspended | Trial primary completion date: Dec 2024 --> Dec 2025

P1, N=68, Completed, Ahon Pharmaceutical Co., Ltd.

Although some discrepancies between the structural and functional improvement in tumor vasculatures were observed after PE-SU5416 × 3 and Seq × 3, cancer-associated fibroblasts (CAFs) and collagen levels were significantly reduced after PE-SU5416 × 2, PE-SU5416 × 3, Seq × 2, and Seq × 3, suggesting that a possible decrease in interstitial fluid pressure due to the reduction in CAFs and collagen would have compensated for vascular function. Furthermore, PE-SU5416 × 2, PE-SU5416 × 3, Seq × 2, and Seq × 3 significantly decreased tumor growth factor-β (TGF-β), an activator of CAFs, in tumor tissues, suggesting that the reduction in TGF-β levels by PE-SU5416 suppresses CAF activation.

Moreover, pathological analysis of tumor and healthy brain tissues unveiled well-defined tumor boundaries, highlighting the capacity of the MPA-Pip-abt-510 probe to precisely visualize the CD36 protein at the molecular level. Given its rapid tumor-targeting abilities, durable retention, and accurate outlining of tumor boundaries, MPA-Pip-abt-510 emerges as a promising CD36-targeted fluorescence contrast agent and expands the toolbox of glioma fluorescent probes for surgical navigation.

When IGF2BP3 was overexpressed, the inhibitory effect of curcumol on angiogenesis in colon cancer tissues was reversed. In summary, curcumol promotes immune cell infiltration in tumor tissues by downregulating IGF2BP3, thereby inhibiting the proliferation and angiogenesis of colon cancer cells.

NTM infections in patients with AIDS generate a prolonged morbidity, frequent readmissions, require an extended combination treatment that may present interactions with ART, and are associated with different complications, including calcium and phosphorus disorders. Its diagnosis is complex in the absence of special blood cultures, requiring a microbiological study in multiple samples and with different techniques, including the support of histopathology.

P4, N=120, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University

P=N/A, N=280, Not yet recruiting, Albert Einstein College of Medicine | Trial completion date: Nov 2028 --> Sep 2029 | Initiation date: Nov 2024 --> Sep 2025 | Trial primary completion date: May 2028 --> Mar 2029

P1/2, N=15, Active, not recruiting, University of Alabama at Birmingham | Completed --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2026 | Trial primary completion date: Dec 2022 --> Dec 2025

An acute tacrolimus exposure reduced PlGF secretion and impaired angiogenesis in primary endothelial cells, without affecting. These findings provide a potential mechanistic basis for tacrolimus to contribute to the endothelial dysfunction contributing to preeclampsia.

The study validates the therapeutic potential of BMSC-Exo/CS TIMP2 in CCA treatment. This innovative approach targets angiogenesis and Wnt/β-catenin signaling, providing a new avenue for more effective and comprehensive CCA therapies.

The results indicated that in the colorectal cancer inflammatory microenvironment, the herb pair Agrimoniae Herba-Coptidis Rhizoma could inhibit angiogenesis via multiple components, targets, and pathways. The anti-angiogenesis effect might be related to the down-regulation of the expression levels of angiogenesis-related factors VEGFA, kdrl, and Flt4 in the VEGFA/VEGFR2 signaling pathway.

RNA sequencing analysis further elucidated that altering NEU3 expression in EA.hy926 cells impacts the Wnt/β-Catenin signaling pathway and c-Myc levels, thereby modulating cellular survival and migration capacity and exerting a regulatory effect on angiogenesis. These findings suggest that targeting NEU3 in the vascular endothelium may represent a promising strategy for anti-angiogenic therapy in tumors.

The patient was diagnosed as having stage IV HER2-positive breast cancer, which was treated with a regimen of trastuzumab (8 mg/kg), pertuzumab (first dose: 840 mg; second dose onward: 420 mg) and docetaxel (75 mg/m2) every 3 weeks. After 4 months of chemotherapy, the patient received complete remission. In conclusion, concomitant use of rifampicin and clarithromycin may increase the blood concentration of docetaxel.

P1, N=40, Recruiting, iOnctura | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

P2, N=34, Active, not recruiting, TaiRx, Inc. | Trial completion date: Dec 2024 --> Dec 2025

Using the clinical-stage ATX inhibitor, IOA-289, we identified connective tissue growth factor (CTGF) as a downstream mediator of ATX signaling in the PDAC CAF-derived cell line, 0082T...Despite the loss of ATX function, extracellular levels of LPA were paradoxically increased, indicating a role for ATX beyond its enzymatic activity and suggesting a role for its LPA chaperone function in the LPA/LPAR signaling in CAFs. As CAFs are the main source for CTGF in the PDAC TME, these findings suggest a role for ATX in promoting pro-tumorigenic microenvironment via modulation of CAF secretion, not only via its LPA-producing activity but also via its LPA chaperone function, providing a potential mechanism for the anti-tumor effects of ATX inhibition.

P2/3, N=1800, Not yet recruiting, McGill University Health Centre/Research Institute of the McGill University Health Centre | Initiation date: Oct 2024 --> Feb 2025

The present findings demonstrated that CCR2 disruption ameliorated PAH in MCT-treated rats, which was associated with the reversal of dysregulated inflammatory pathways and vascular dysfunction and synergized with tadalafil. These findings suggest that CCR2 may be a therapeutic target in intractable PAH patients with a certain CCR2-related inflammatory phenotype and refractory to conventional pulmonary vasodilators.

The observed differences in efficacy between various angiogenesis inhibitors highlight the importance of personalized treatment approaches. Further research is warranted to explore the long-term benefits of these combination strategies and refine them to obtain optimal patient outcomes.

This study validated the anti-tumor efficacy of Lipo-HNK against NSCLC. Lipo-HNK reduced the infiltration of MDSCs and M2 macrophages by inhibiting the PI3K/Akt pathway and enhanced the therapeutic effects of ICIs. These findings provide evidence and new insights into Lipo-HNK as a promising anti-cancer drug for NSCLC treatment, highlighting its potential to overcome resistance to current ICI therapies.

P1, N=200, Not yet recruiting, University of Virginia | Phase classification: P1/2 --> P1 | Initiation date: Jul 2024 --> Jan 2025

P4, N=2500, Recruiting, Duke University | Trial completion date: Apr 2026 --> Oct 2026 | Trial primary completion date: Apr 2026 --> Oct 2026

Additionally, we found that ATL-I could decrease the level of EPAS1, which was upregulated in sunitinib-resistant cells, thus reversing sunitinib resistance. Collectively, our findings demonstrate that ATL-I is a robust antiangiogenic and antitumor lead compound with potential clinical application for ccRCC therapy.

In this preclinical study, an oncolytic reovirus (RC402) is orally administered to induce antitumor immunity...Oral reovirus treatment is most effective when combined with αPD-1(L1) and/or αCTLA-4, leading to complete colon tumor regression and protective immune memory. Collectively, oral reovirus virotherapy is a feasible and effective immunotherapeutic strategy in preclinical studies.

Knockdown of USP9X attenuated the regulatory effects of MSC-sEV on Ang-2 expression, LSEC angiogenesis, and the progression of MASH. In conclusion, our findings indicate that USP9X delivered via MSC-sEV can suppress LSEC angiogenesis and alleviate MASH-induced liver fibrosis through the IκBα/NF-κB/Ang-2 signaling pathway.